Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo. Issue 1 (1st January 2002)

• Record Type: Journal Article
• Authors: Newby, D E; Witherow, F N; Wright, R A; Bloomfield, P; Ludlam, C A; Boon, N A; Fox, K A A; Webb, D J
• Is Part Of: Heart. Volume 87:Issue 1(2002)
• Page Start: 48
• Page End: 53
• Publication Date: 2002-01-01
• Subjects: fibrinolytic factors -- hypercholesterolaemia -- lipid lowering treatment; ELISA, enzyme linked immunosorbent assay -- FBF, forearm blood flow -- Hct, Haematocrit -- LDL, low density lipoprotein -- PAI-1, plasminogen activator inhibitor type 1 -- t-PA, tissue plasminogen activator -- WOSCOPS, west of Scotland coronary prevention study; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heart.87.1.48
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hypercholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocholesterolaemic controls. Design: Parallel group comparison and double blind randomised crossover. Setting: University hospital. Patients: Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and eight matched normocholesterolaemic controls (< 5.5 mmol/l). Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms during unilateral brachial artery infusions of the endothelium dependent vasodilator substance P (2–8 pmol/min) and the endothelium independent vasodilator sodium nitroprusside (1–4 μg/min). Interventions: In patients, measurements were made on three occasions: at baseline and after six weeks of placebo or pravastatin 40 mg daily administered in a double blind randomised crossover design. Main outcome measures: Acute release of t-PA. Results: Compared with patients, in normocholesterolaemic control subjects substance P caused greater dose dependent increases in forearm blood flow (p < 0.05) but similar increases in plasma t-PA antigen and activity concentrations. During pravastatin treatment in patients, total serum cholesterol fell by 22% from a mean (SEM) of 8.1 (0.3) to 6.4 (0.4) mmol/l (p = 0.002) and substance P induced vasodilatation was no longer significantly impaired in comparison with controls. However, despite reproducible responses, pravastatin treatment was not associated with significant changes in basal or substance P induced t-PA release. Conclusions: Hypercholesterolaemia and lipid lowering treatment cause no demonstrable effects on acute substance P induced t-PA release in vivo. This suggests that the preventative benefits of lipid lowering treatment are unlikely to be mediated by improvements in endogenous fibrinolysis.